Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.